Publication & Citation Trends
Publications
0 total
Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial.
Cited by 21
Semantic Scholar
IMpower010: Final disease-free survival (DFS) and second overall survival (OS) interim results after ≥5 years of follow up of a phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA non-small cell lung cancer (NSCLC).
Cited by 14
Semantic Scholar
OA01.04 IMpower010 5-y Subgroup Analysis and Relapse Patterns: Phase 3 Study of Atezolizumab vs BSC in Stage II-IIIA NSCLC
Cited by 6
Semantic Scholar
Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. OA
Cited by 217
Semantic Scholar
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.
Cited by 983
Semantic Scholar
IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC).
Cited by 1
Semantic Scholar
Investigation of erythrocyte aggregation in patients with laryngeal cancer OA
Cited by 0
Semantic Scholar
Research Topics
Cancer Immunotherapy and Biomarkers
(4)
Lung Cancer Treatments and Mutations
(4)
Lung Cancer Diagnosis and Treatment
(2)
Gastric Cancer Management and Outcomes
(1)
Peptidase Inhibition and Analysis
(1)
Affiliations
National University Zaporizhzhia Polytechnic